BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -54.57% | 40.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -54.57% | 40.46% | |||
| Cost of Revenue | -52.38% | 16.67% | |||
| Gross Profit | -55.10% | 47.84% | |||
| SG&A Expenses | 34.18% | 297.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.91% | 1.04% | |||
| Operating Income | -53.42% | 4.17% | |||
| Income Before Tax | -128.86% | 75.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -128.86% | 75.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -41.76% | 75.20% | |||
| EBIT | -53.42% | 4.17% | |||
| EBITDA | -59.45% | 1.83% | |||
| EPS Basic | -25.00% | 76.47% | |||
| Normalized Basic EPS | 0.00% | 80.00% | |||
| EPS Diluted | -25.00% | 76.47% | |||
| Normalized Diluted EPS | 0.00% | 80.00% | |||
| Average Basic Shares Outstanding | 2.12% | 10.02% | |||
| Average Diluted Shares Outstanding | 2.12% | 10.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||